Conditions: Schizophrenia
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 119
Healthy volunteers: no

Brief summary:
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Aripiprazole
Intervention descriptions: intervention 1: Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country

Protocol document: